Entrada Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in February and March 2026. CEO Dipal Doshi will take part in fireside chats at the Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 4:00 p.m. ET and the TD Cowen Health Care Conference on Mar 3, 2026 at 2:30 p.m. ET.

Both presentations offer live webcasts and replays available on the company investor relations website for 90 days after each event.

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences.

Guggenheim Emerging Outlook: Biotech Summit 2026
Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY.

TD Cowen 46^th Annual Health Care Conference
Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA.

Live webcasts will be available on the Investor Relations section of the Company’s website at www.entradatx.com. Replays will be available on the Entrada website for 90 days following the events.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com

FAQ

When will Entrada Therapeutics (TRDA) present at the Guggenheim Emerging Outlook: Biotech Summit?

Entrada will present on February 11, 2026 at 4:00 p.m. ET with CEO Dipal Doshi in a fireside chat. According to the company, the session is in New York and will be webcast live on the investor relations website.

What time and date is Entrada Therapeutics (TRDA) scheduled for TD Cowen 46th Annual Health Care Conference?

The TD Cowen presentation is on March 3, 2026 at 2:30 p.m. ET featuring CEO Dipal Doshi in a fireside chat. According to the company, the event is in Boston and will be available via live webcast.

Where can investors watch Entrada Therapeutics (TRDA) conference webcasts and replays?

Investors can watch live webcasts and replays on the company's investor relations website at www.entradatx.com. According to the company, replays will remain available for 90 days after each event.

Who from Entrada Therapeutics (TRDA) will speak at the February and March 2026 conferences?

Dipal Doshi, CEO of Entrada Therapeutics, will appear in fireside chats at both conferences. According to the company, Doshi will discuss company updates during live webcasts accessible to investors.

Will Entrada Therapeutics (TRDA) provide replays of the investor conference presentations?

Yes, replays will be available on the company's investor relations website for 90 days following each event. According to the company, the replays cover the full fireside chat sessions and are accessible online.